Covered recipient · General Payments record
CAMILA MASIAS
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
General Payments · PY2019–2024
$63,899.27
- Reported across 69 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $4,691.88 | 2 |
| Food and Beverage | $156.53 | 7 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| GENZYME CORPORATION | $3,359.05 | 3 |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,419.85 | 2 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $47.86 | 3 |
| PFIZER INC. | $21.65 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (9)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| GENZYME CORPORATION | $16.15 | 08/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139740604 | CMS |
| GENZYME CORPORATION | $47.90 | 10/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139740656 | CMS |
| GENZYME CORPORATION | $3,295.00 | 10/01/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1139740658 | CMS |
| Novartis Pharmaceuticals Corporation | $14.44 | 03/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1087052318 | CMS |
| Novartis Pharmaceuticals Corporation | $14.81 | 04/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1087052324 | CMS |
| Novartis Pharmaceuticals Corporation | $18.61 | 08/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1087052336 | CMS |
| PFIZER INC. | $21.65 | 06/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131515894 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $22.97 | 01/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137630811 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,396.88 | 02/07/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1137630813 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.